Literature review synthesizes Schisandra chinensis effects on gut microbiota and metabolic pathways across multiple conditions.

Photo by Dmytro Vynohradov / Unsplash

Frontiers in Medicine Published April 19, 2026 Medically reviewed April 25, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note that efficacy of Schisandra chinensis in humans remains unvalidated by high-quality clinical trials.

This literature review evaluates the potential of Schisandra chinensis across conditions including ulcerative colitis, alcohol-associated liver disease, and type 2 diabetes mellitis. The scope encompasses the plant's influence on gut microbiota composition, intestinal barrier function, and metabolic pathways. The review synthesizes findings from 61 studies, suggesting that S. chinensis rich in polysaccharides and lignans may rebalance gut microbiota and repair intestinal barrier function. Additionally, the authors note that lignans may modulate bile acid production and that the plant may increase short-chain fatty acids levels.

The review further suggests that Schisandra chinensis may regulate metabolic pathways and alleviate symptoms. Despite these potential benefits, the authors highlight significant limitations. They state that the precise mechanisms by which S. chinensis regulates the gut microbiota remain unclear. Furthermore, high-quality clinical trials are lacking to validate the efficacy of S. chinensis in humans.

Given these gaps, the practice relevance is currently uncertain. The authors caution that while the data suggests potential therapeutic directions, the evidence does not yet support definitive clinical recommendations. Clinicians should interpret these findings as preliminary observations rather than established treatment options, pending further high-quality research.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

BackgroundTo clarify the mechanism by which Schisandra chinensis regulates the disease-related gut microbiota and to identify potential directions for future research.MethodsRelevant literature published between 2020 and 2025 was retrieved from Google scholar and NCBI PubMed. Two authors screened the literature based on titles and abstracts, followed by full-text screening by another two authors to ensure the inclusion of eligible studies.ResultsWe found in 61 studies that S. chinensis rich in polysaccharides and lignans, which are primary bioactive compounds involved in modulating gut microbiota composition. These compounds have been extensively studied for their ability to rebalance gut microbiota, repair the intestinal barrier function, increase short-chain fatty acids levels, and regulate metabolic pathways. Therefore, S. chinensis alleviates the symptoms caused by ulcerative colitis, antibiotic-associated diarrhea, alcohol-associated liver disease, type 2 diabetes mellitus, Alzheimer’s disease, non-alcoholic fatty liver disease, systemic inflammation, and neurobehavioral alterations associated with mental illness. Additionally, another study suggested that lignans influence bile acid production by modulating gut microbiota.ConclusionCurrent research on S. chinensis regulate gut microbiota, which have demonstrated therapeutic effects in disease. However, the precis mechanisms of S. chinensis regulated the gut microbiota remain unclear, and high-quality clinical trials are lacking to validate the efficacy of S. chinensis in humans.